menu
    • menu

    Company profile for Aileron Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aileron Therapeutics (NASDAQ:ALRN) is the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases. Our lead product candidate ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt its interactions with both its endogenous inhibitors, MDMX and MDM2. For p53 wild-type tumors, ALRN-6924 can resto...
    Aileron Therapeutics (NASDAQ:ALRN) is the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases. Our lead product candidate ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt its interactions with both its endogenous inhibitors, MDMX and MDM2. For p53 wild-type tumors, ALRN-6924 can restore p53-dependent tumor suppression. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of solid and hematological cancers

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aileron TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    490 Arsenal Way Watertown, MA 02472
    Telephone
    Telephone
    617-995-0900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aileronrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aileron Therapeutics Announces Rebranding to Rein Therapeutics
    Aileron Therapeutics Announces Rebranding to Rein Therapeutics

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aileron-therapeutics-announces-rebranding-to-rein-therapeutics-302348094.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    Aileron Therapeutics Reports Q3 2024 Results & Highlights
    Aileron Therapeutics Reports Q3 2024 Results & Highlights

    14 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aileron-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights-302306387.html

    PR NEWSWIRE
    14 Nov 2024
    Share Share
    Aileron Reports Positive Phase 1b Data for IPF Drug LTI-03
    Aileron Reports Positive Phase 1b Data for IPF Drug LTI-03

    13 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aileron-therapeutics-announces-positive-topline-data-from-cohort-2-of-the-phase-1b-clinical-trial-of-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-302303568.html

    PR NEWSWIRE
    13 Nov 2024
    Share Share
    Aileron & Advancium Announce Deal for ALRN-6924 in Retinoblastoma
    Aileron & Advancium Announce Deal for ALRN-6924 in Retinoblastoma

    31 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aileron-therapeutics-and-advancium-health-network-announce-an-exclusive-option-agreement-for-the-acquisition-of-alrn-6924-for-retinoblastoma-302292196.html

    PR NEWSWIRE
    31 Oct 2024
    Share Share
    Aileron Therapeutics To Present LTI-03 Data In Pulmonary Fibrosis
    Aileron Therapeutics To Present LTI-03 Data In Pulmonary Fibrosis

    12 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-at-the-22nd-international-colloquium-on-lung-and-airway-fibrosis-302274268.html

    PR NEWSWIRE
    12 Oct 2024
    Share Share
    Aileron Completes Enrollment In LTI-03 IPF Phase 1b Trial
    Aileron Completes Enrollment In LTI-03 IPF Phase 1b Trial

    23 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aileron-therapeutics-completes-enrollment-in-cohort-2-of-the-ongoing-phase-1b-clinical-trial-evaluating-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-302254831.html

    PR NEWSWIRE
    23 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search